What question did this study set out to answer?

This research aims to assess the duration of good visual acuity achieved with different anti-VEGF therapies for AMD.

Evaluation of the Duration of Good Visual Acuity During Anti-VEGF Therapy for Age-Related Macular Degeneration in Routine Clinical Practice

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows aflibercept enhances visual acuity duration in AMD treatment, indicating better outcomes than ranibizumab.

This research aims to assess the duration of good visual acuity achieved with different anti-VEGF therapies for AMD.
Retrospective analysis of clinical database from 2015 to 2023.
Evaluation of visual acuity using ETDRS score and time in range parameters.
Comparison of treatment outcomes between aflibercept and ranibizumab patients.
Aflibercept group had a higher average time in range than ranibizumab (60.90 vs 56.55 days, p < 0.001).
Both treatments showed significant improvement in visual acuity (p < 0.001).
Aflibercept patients more likely to achieve >70 ETDRS letters at follow-up (OR: 1.10, p < 0.001).

Gyenes et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark